Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

8 (p < 0.0001) and 20.7 at Week 16 (p = 0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months.

"We were pleased to see consistent results across both NEUVENGE trials, particularly as they further substantiate the tolerability of this therapeutic approach," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer. "These data provide further evidence of the promise of our active cellular immunotherapy platform which also includes PROVENGE(R) (sipuleucel-T), our lead product candidate currently in late-stage development for prostate cancer. We expect to receive the final data analysis from our ongoing Phase 3 PROVENGE trial in mid-2009 and look forward to discussing further clinical development plans for NEUVENGE and our immunotherapy pipeline after that time."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal, bladder and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commerc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. ... had received a complete response letter from the ... its New Drug Application ("NDA") for Onrigin(TM) (laromustine) ... indicates that the FDA cannot approve the Company,s ... to address remaining issues. ,, Alan Kessman, Chief ...
(Date:12/14/2009)... -- Cancer patients in Finland have gained access ... RapidArc® radiotherapy technology from Varian Medical Systems (NYSE: ... radiotherapy clinic in the Nordic region. Clinicians at ... and precise form of radiotherapy to treat patients ... abdomen and prostate. ,, RapidArc, which enables clinicians ...
(Date:12/14/2009)... 14 According to Millennium Research Group ... intelligence, increased use of safety devices for small-bore ... a key driver of the enteral feeding device ... new US and European Markets for Enteral ... giving set segment will experience the greatest impact ...
Breaking Medicine Technology:Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 1Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 4Jillian Michaels Americas Toughest Trainer Announces New Line of Weight Loss Supplements 50243 1Jillian Michaels Americas Toughest Trainer Announces New Line of Weight Loss Supplements 50243 2Jillian Michaels Americas Toughest Trainer Announces New Line of Weight Loss Supplements 50243 3Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 1Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 3
... /PRNewswire-FirstCall/ --,Phosphagenics Limited (AIM: PSG) announced today ... 1b clinical trial to demonstrate the,efficacy and ... transdermal,insulin product, TPM-02/Insulin, containing long-acting insulin.,The trial ... quarter of,2007. , TPM-02/Insulin gel is being ...
... to be Part of Data Package Required to ... -- Novavax,Inc. said today that it has received ... ferrets inoculated with its pandemic,influenza vaccine, paving the ... this year. , In the study, ferrets were ...
Other Medicine Technology:Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 3
(Date:12/14/2009)... Kurisko practiced in Canada for 13 years under government controlled health ... a free-market economy. In speaking engagements and in his new book, ... of the fragility of such a system and its threat to ... ... -- Lee Kurisko , a diagnostic radiologist from Minnesota, warns ...
(Date:12/14/2009)... of Thousands of New Chronic Hepatitis Infections Annually ... approved by Congress providing for federal funding of ... reduce tens of thousands of new viral hepatitis ... the National Viral Hepatitis Roundtable (NVHR) ... the FY 2010 Consolidated Appropriations bill approved by ...
(Date:12/14/2009)... benefited men whose disease had been treated, hadn,t spread, ... Exercise appears to reduce the risk of death in ... which began in January 1986, included 668 men who,d ... III colon cancer that had not spread (nonmetastatic cancer). ... asked them about any new cancer and disease diagnoses, ...
(Date:12/14/2009)... diabetes and obesity are linked to an increased risk ... insulin glargine (a synthetic insulin preparation marketed under the ... risk of certain cancers than other insulins or oral ... to control for important factors such as obesity that ... other hand, a large randomized trial designed to examine ...
(Date:12/14/2009)... Biopsy , ... Newport News, VA ... that the U.S. Food and Drug Administration (FDA) has granted ... guidance. , , ,GammaLMc® is a complementary technology to ... (GL) system will help doctors accurately locate breast lesions and ...
Breaking Medicine News(10 mins):Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2
... Financing Led by Clarus Ventures -MOUNT OLIVE, N.J., Jan ... development of programmable implantable pumps for targeted delivery of ... $25 million.Clarus Ventures, a life sciences venture capital firm, ... investment by FatBoy Capital, LP. In conjunction with ...
... generation of health and longevity products with ... & mineral supplement concentrate. AimCa++DONAN is ideal ... in pre and post-menopausal phases, baby-boomers, and ... products of Aim Pharmakon are highly efficacious ...
... STOCKHOLM, January 12 Sweden The Swedish investment,company Karolinska ... Oy that develops stem cell and other tissue engineering ... In 2007 EvoStem Finland Oy introduced its ... service for tendon and ligament injuries,in horses. TendoStem(R) is ...
... HotHead Technologies, Inc., an,Atlanta-based enterprise committed to ... it is working closely with Schutt,Sports to ... which can,detect potential heat stroke in a ... activities was officially announced at the American ...
... scientific study in which victims of a brain injury were more ... of spirituality might actually be caused by brain damage among victims ... ... Denver, CO (PRWEB) January 11, 2009 -- LegalView, the most ...
... bacteria in King Nut brand; almost 400 Americans in 42 ... 10(HealthDay News) -- Health officials in the state of Minnesota ... one brand of peanut butter distributed to schools and hospitals, ... has struck in 42 states so far. , Officials from ...
Other Medicine News:Health News:InSet Technologies Completes $25 Million Financing 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Karolinska Development Invests in EvoStem Finland Oy 2Health News:HotHead Technologies Working with Schutt Sports to Develop 'Smart' Helmet 2Health News:HotHead Technologies Working with Schutt Sports to Develop 'Smart' Helmet 3Health News:LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage 2Health News:LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage 3Health News:LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage 4Health News:Peanut Butter Eyed as Source of Salmonella Outbreak 2Health News:Peanut Butter Eyed as Source of Salmonella Outbreak 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: